Unique Findings With Binimetinib Plus Imatinib in Advanced GIST

February 19, 2021

Ping Chi, MD, a medical oncologist, and Geoffrey Beene Junior Faculty chair at Memorial Sloan Kettering Cancer Center, reviews the results of a phase 2 study of binimetinib plus imatinib as treatment of patients with untreated advanced gastrointestinal stromal tumors.

Ping Chi, MD, a medical oncologist, and Geoffrey Beene Junior Faculty chair at Memorial Sloan Kettering Cancer Center, reviews the results of a phase 2 study of binimetinib (Mektovi) plus imatinib (Gleevec) as treatment of patients with untreated advanced gastrointestinal stromal tumors.

Ping says that on top of achieving the primary end point of objective response, the select subgroup of patients was able to undergo resection. There were 7 patients who were considered unresectable at baseline, and 6 of them were resectable after treatment with the combination.

It was also notable in the study that the pathological responses in patients were deeper compared to the traditional RECIST responses, Ping explains. Looking ahead, she believes responses should be evaluated beyond.